BIO
Oncolytic viruses represent a promising but highly complex class of cancer therapeutics, where successful development depends not only on achieving viral yield but on preserving the biological characteristics that drive therapeutic activity throughout scale-up and GMP manufacturing. As developers advance programs from research to clinical production, early consideration of raw materials, intermediate stability, analytical methods, process scalability, and regulatory expectations can reduce comparability risk, avoid costly redevelopment, and support a smoother path to commercialization.
In this article, we explore the critical factors that enable oncolytic viruses to transition from research concepts into manufacturable cancer therapies. The paper examines strategies for designing scalable GMP-ready processes, managing material and supplier selection, assessing intermediate stability during scale-up, developing robust product-specific analytical methods, and leveraging risk-based approaches to process development. It also highlights the value of flexible CDMO partnerships that adapt manufacturing solutions to the unique requirements of each viral product while supporting efficient technology transfer and regulatory readiness.
What you'll explore
- Why preserving viral identity, infectivity, potency, and biological function throughout manufacturing is critical to clinical success
- How early GMP-focused decisions on materials, consumables, equipment, and supplier selection can reduce future development and comparability challenges
- How product-specific analytical methods, potency assays, and assay qualification strategies provide the insights needed to guide process development and control
Fill out the form below to access the white paper